The symptomatic control of cytostatic drug-induced emesis. A recent history and review.
This article outlines the historical development of anti-emetic therapies and reviews the pathophysiology and clinical aspects of cytostatic drug-induced vomiting. The methodology and the factors affecting the results of clinical trials with anti-emetics are discussed. Advances in knowledge of the role of 5-hydroxytryptamine in cytostatic drug-induced vomiting have improved current anti-emetic therapy with the development of 5-HT3 receptor antagonists such as granisetron. Early trials show granisetron to be a very effective anti-emetic and suggest useful advantages over the regimens currently considered to be standard therapy for prophylaxis and treatment of cytostatic drug-induced emesis.
Joss
R A
RA
Department of Medicine, Kantonsspital, Lucerne, Switzerland.
Brand
B C
BC
Buser
K S
KS
Cerny
T
T
D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017829:Granisetron; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced*
D000932:Antiemetics; D000970:Antineoplastic Agents; D017829:Granisetron; D007191:Indazoles; D012702:Serotonin Antagonists